Extracellular vesicles for renal therapeutics: State of the art and future perspective

41Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

With the ever-increasing burden of kidney disease, the need for developing new therapeutics to manage this disease has never been greater. Extracellular vesicles (EVs) are natural membranous nanoparticles present in virtually all organisms. Given their excellent delivery capacity in the body, EVs have emerged as a frontier technology for drug delivery and have the potential to usher in a new era of nanomedicine for kidney disease. This review is focused on why EVs are such compelling drug carriers and how to release their fullest potentiality in renal therapeutics. We discuss the unique features of EVs compared to artificial nanoparticles and outline the engineering technologies and steps in developing EV-based therapeutics, with an emphasis on the emerging approaches to target renal cells and prolong kidney retention. We also explore the applications of EVs as natural therapeutics or as drug carriers in the treatment of renal disorders and present our views on the critical challenges in manufacturing EVs as next-generation renal therapeutics.

Cite

CITATION STYLE

APA

Tang, T. T., Wang, B., Lv, L. L., Dong, Z., & Liu, B. C. (2022, September 1). Extracellular vesicles for renal therapeutics: State of the art and future perspective. Journal of Controlled Release. Elsevier B.V. https://doi.org/10.1016/j.jconrel.2022.06.049

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free